Drug Information - message

What medications are used for urothelial carcinoma after drug resistance develops? The ADC drug Padcev significantly improves survival.

What medicine to use after urothelial carcinoma is resistant to drugs? ADC drug Padcev significantly improves survival

Urothelial carcinoma (UC) is the most common bladder tumor. Almost half of advanced UC patients are not eligible for cisplatin-based chemotherapy. Many of these patients have no response or no response to immunotherapy. They urgently need more treatment options, but there is currently no standard care plan.. According to reports, the new anti-cancer drug Padcev is a first-of-its-kind ADC drug, which has previously been approved for the treatment of patients with locally advanced or metastatic UC who have progressed after receiving anti-cancer drugs.

Padcev International Research Data

Open label, randomized, multi-center EV-301 test (ClinicalTrials.gov Identifier: NCT03474107) Recruited 608 patients with locally advanced or metastatic UC who received PD-1/PD-L1 inhibitors and platinum chemotherapy. Patients were randomly assigned in a 1:1 manner and received a dose of 1.25 mg/kg of Padcev (n=301) or the monotherapy selected by the researcher (docetaxel, paclitaxel or vinfunin) (n=301) on the 1st, 8th, and 15th days of the 28-day cycle.307). The main efficacy endpoints are total survival (OS), and the main and secondary efficacy endpoints are progress-free survival (PFS) and total remission rate (ORR). The researchers used Version 1.1 of the solid tumor response evaluation criteria for evaluation.

The trial results showed that the median overall survival (OS) in the Padcev group was 12.9 months (95% CI, 10.6–15.2 months), compared to 9.0 months (95% CI, 8.1–10.7 months) in the chemotherapy group (hazard ratio [HR], 0.70; 95% CI, 0.56–0.89; P=0.0014). The median progression-free survival (PFS) was 5.6 months (95% CI, 5.3–5.8 months), compared to 3.7 months (95% CI, 3.5–3.9 months) in the chemotherapy group (HR, 0.62; 95% CI, 0.51–0.75; P<0.0001). The ORR in the Padcev group was 40.6% (95% CI, 34.9%-46.5%), while that of chemotherapy was 17.9% (95% CI, 13.7%-22.8%) (P<0.0001).

The efficacy of cisplatin-based chemotherapy was evaluated in cohort 2 of the EV-201 trial (ClinicalTrials.gov identifier: NCT03219333), a single-arm, multi-cohort, international trial involving 89 patients with previously treated locally advanced or metastatic UC receiving a PD-1/PD-L1 inhibitor. The primary efficacy endpoint was confirmed ORR, assessed by a blinded, independent central review, and the key secondary efficacy endpoint was duration of response. The confirmed ORR in the Padcev treatment group was 51% (95% CI, 39.8%–61.3%), with 22% achieving complete response, and a median duration of response of 13.8 months (95% CI, 6.4 months to inestimable).

The most common adverse events, including laboratory abnormalities, that occur in at least 20% of patients are hair loss, anemia, diarrhea, dry skin, taste disorders, fatigue, loss of appetite, nausea, peripheral neuropathy, itching, skin rashes, and weight loss; aspartic acid and alanine aminotransferase, creatinine, glucose, An increase in lipase and urate; a decrease in albumin, hemoglobin, lymphocytes, neutrophils, phosphates, platelets, and sodium.

Padcev drug introduction

Drug name: Enfortumab vedotin

Product name: Padcev

Manufacturer: Astellas Pharma

Padcev is a first-in-class antibody drug coupling (ADC) that targets a cell surface protein highly expressed in bladder cancer. The drug is composed of enfortumab, a human IgG1 monoclonal antibody targeting connectin-4 (Nectin-4), coupled with the cytotoxic agent MMAE (monomethyl auristatin E, monomethyl auristatin E, a microtubule disruptor). Nectin-4 is a highly expressed therapeutic target in a variety of solid tumors, including urothelial carcinoma. In December 2019, Padcev received accelerated approval from the U.S. FDA for the treatment of patients with locally advanced or metastatic urothelial cancer.

Reminder: Padcev is the first ADC drug approved for the treatment of UC, and it is also the first drug approved for patients with locally advanced or metastatic UC who have previously received platinum-containing chemotherapy and a PD-1 or PD-L1 inhibitor.